BEAM241220P29000
- 3.70
- 0.000.00%
Beam Therapeutics Newsroom
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
ARKK's Holdings Ranked by SA Quant Grades
CRISPR, Beam, Other Gene Editing Names up Significantly
Beam Therapeutics Insider Sold Shares Worth $1,347,050, According to a Recent SEC Filing
Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com
Beam Therapeutics Is Maintained at Sector Perform by RBC Capital
Beam Stock Rebounds as Leerink Upgrades Despite Fatality in Gene Editing Trial
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
Scotiabank Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $24
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $31 to $69
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
Beam Therapeutics Analyst Ratings
Express News | Beam Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $39 From $27
Express News | Beam Therapeutics Inc : RBC Cuts Target Price to $24 From $27
JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript Summary
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript